Howard Horn Sells 7,942 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 7,942 shares of the stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at $3,095,132.77. This trade represents a 7.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $33.43 on Thursday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $25.81 and a 1 year high of $57.99. The stock has a market cap of $3.22 billion, a P/E ratio of -6.05 and a beta of 0.21. The stock has a 50-day simple moving average of $29.98 and a 200-day simple moving average of $32.94.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business’s quarterly revenue was up 13.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analyst Weigh In

RARE has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Wells Fargo & Company dropped their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, July 10th. Canaccord Genuity Group reduced their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a report on Friday, August 8th. Guggenheim reissued a “buy” rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Finally, Wedbush cut their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.50.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Ultragenyx Pharmaceutical by 6,279.5% during the 1st quarter. GAMMA Investing LLC now owns 27,049 shares of the biopharmaceutical company’s stock worth $979,000 after acquiring an additional 26,625 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 19.7% during the first quarter. Oppenheimer Asset Management Inc. now owns 7,140 shares of the biopharmaceutical company’s stock worth $259,000 after purchasing an additional 1,173 shares during the last quarter. Peregrine Capital Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 3.4% during the first quarter. Peregrine Capital Management LLC now owns 169,467 shares of the biopharmaceutical company’s stock worth $6,136,000 after purchasing an additional 5,579 shares during the period. WCM Investment Management LLC grew its position in Ultragenyx Pharmaceutical by 49.1% in the 1st quarter. WCM Investment Management LLC now owns 202,213 shares of the biopharmaceutical company’s stock valued at $7,648,000 after buying an additional 66,604 shares during the last quarter. Finally, GF Fund Management CO. LTD. increased its stake in Ultragenyx Pharmaceutical by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,364 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 425 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.